NCT04395456View on ClinicalTrials.gov

A Study of the C3 Inhibitor AMY-101 in Patients With ARDS Due to COVID-19 (SAVE)

PHASE2UnknownINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

September 30, 2021

Primary Completion Date

September 30, 2022

Study Completion Date

December 31, 2022

Conditions
Acute Respiratory Distress Syndrome Due to SARS-CoV-2 Infection (Severe COVID19)
Interventions
DRUG

AMY-101

C3 complement inhibitor

OTHER

WFI 5% glucose

Placebo

Sponsors
All Listed Sponsors
lead

Amyndas Pharmaceuticals S.A.

INDUSTRY

NCT04395456 - A Study of the C3 Inhibitor AMY-101 in Patients With ARDS Due to COVID-19 (SAVE) | Biotech Hunter | Biotech Hunter